The Supreme Court appears split over a major lawsuit against Bayer regarding Roundup, the world's most widely used herbicide. Thousands of plaintiffs claim glyphosate, Roundup's active ingredient, caused their cancer. The court's decision will shape whether these cases proceed or face dismissal.
The case hinges on a technical question: whether federal pesticide regulations preempt state-level lawsuits. Bayer argues that the Environmental Protection Agency already determined glyphosate is safe, so states cannot impose stricter standards. Plaintiffs' lawyers counter that people deserve the right to sue under state law when they believe a product harmed them.
The EPA has consistently found no link between glyphosate and cancer in humans. However, the International Agency for Research on Cancer classified it as "probably carcinogenic" in 2015. This disagreement between agencies fuels the legal dispute.
The outcome affects not just Roundup users but the broader legal landscape for pharmaceutical and chemical injury cases. A ruling favoring Bayer could block thousands of pending lawsuits. A ruling favoring plaintiffs could expose manufacturers to widespread state-level litigation. The court's divided appearance suggests no easy consensus exists on balancing federal safety approval against individual legal rights.